Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
Aberdeen Group plc and its subsidiary abrdn Inc. report updated passive ownership in uniQure N.V. under Amendment No. 4 to Schedule 13G. As of June 30, 2026, they beneficially own 2,848,117 ordinary shares, representing 4.52% of the outstanding ordinary-share class.
The group reports no sole voting or dispositive power over these shares. All 2,848,117 shares are held with shared voting and shared dispositive power, principally through abrdn Inc. on behalf of underlying clients, reflecting ownership of less than 5% of the class.
JPMorgan Chase & Co. has reported beneficial ownership of 4,866,211 Ordinary Shares of uniQure N.V., representing 7.0% of this class of securities. The shares are identified by CUSIP N90064101 and relate to Ordinary Shares with a par value of 0.05.
JPMorgan has sole voting power over 4,598,521 shares and shared voting power over 10 shares. It has sole dispositive power over 4,866,201 shares and shared dispositive power over 10 shares. The position is held through subsidiaries including J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, JPMorgan Asset Management (UK) Limited, and J.P. Morgan Investment Management Inc.
uniQure N.V.’s CEO Matthew C. Kapusta exercised stock options and sold shares in a pre-planned trade. On July 2, 2026, he exercised options for 21,082 Ordinary Shares at an exercise price of $19.39 per share and converted them into common equity.
That same day, he sold 21,082 Ordinary Shares in three open-market transactions at reported weighted average prices of $44.43, $45.43, and $45.89, with actual sale prices ranging from $44.10 to $46.10. Following these transactions, he directly owned 519,227 Ordinary Shares. The filing states the trades were executed under a Rule 10b5-1 sales plan adopted on October 5, 2025, indicating they were pre-scheduled.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an exercise-and-sell transaction in Ordinary Shares. On June 30, 2026, he sold a total of 30,000 Ordinary Shares in open-market sales at weighted average prices of $46.40 and $46.46 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on September 26, 2025.
On the same date, he exercised stock options to acquire 10,000 Ordinary Shares at a $5.59 exercise price, reducing his option position tied to that grant. Following these transactions, he directly owns 148,235 Ordinary Shares and holds 50,500 stock options expiring on March 1, 2034.
uniQure N.V. director Jack Kaye reported option exercises and share sales. On June 30, 2026, he exercised stock options for a total of 21,167 Ordinary Shares at exercise prices of $20.18 and $37.00, then sold the same number of shares in open-market transactions around $46.43–$46.49 per share. These trades were carried out under a pre-arranged Rule 10b5-1 sales plan adopted on June 16, 2025. After these transactions, he directly owned 25,996 Ordinary Shares.
The filing provides notice of proposed sales of ordinary shares of UniQure N.V. by an affiliate, including a scheduled stock option exercise and sale of 21,082 shares on 07/02/2026 through Citigroup Global Markets for cash. The excerpt also lists multiple open-market sales by Matthew C. Kapusta during June 2026 with specific share counts and gross proceeds.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an open-market sale of 1,434 ordinary shares at a weighted average price of $46.86 per share. The shares were sold automatically upon vesting of restricted share units solely to cover estimated withholding taxes, and were not a discretionary trade. Following this transaction, he holds 168,235 shares directly.
Uniqure N.V. filed a Form 144 reporting proposed sales and recent dispositions of its Ordinary Shares. The filing lists a proposed sale of 30,000 Ordinary Shares through Citigroup Global Markets, Inc., dated 06/30/2026. It also records a 10,000-share option exercise under a Rule 10b5-1 plan on 06/30/2026 and 20,000 vested restricted shares on 06/26/2025. The filing shows past sales in the three months including 45,000 shares sold on 05/08/2026 for $1,127,435.50 and 1,434 shares sold on 06/26/2026 for $67,197.10.
Jack Kaye submitted a Form 144 reporting proposed sales of 21,167 Ordinary Shares on 06/30/2026, citing a stock option exercise pursuant to a 10b5-1 plan with cash proceeds. The filing lists three recent dispositions in June 2026 totaling 9,933 shares sold for cash.
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported option exercises and share sales in Ordinary Shares. On June 24–25, 2026, he exercised stock options to acquire 32,844 shares at $31.71 per share and sold 35,412 shares in open-market transactions around $50 per share. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 5, 2025. Following these transactions, he directly holds 519,227 Ordinary Shares.